A detailed history of Zeke Capital Advisors, LLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Zeke Capital Advisors, LLC holds 5,113 shares of ASND stock, worth $763,575. This represents 0.04% of its overall portfolio holdings.

Number of Shares
5,113
Previous 3,851 32.77%
Holding current value
$763,575
Previous $398,000 56.78%
% of portfolio
0.04%
Previous 0.03%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$99.42 - $131.97 $125,468 - $166,546
1,262 Added 32.77%
5,113 $624,000
Q1 2022

May 13, 2022

BUY
$102.18 - $135.75 $85,218 - $113,215
834 Added 27.64%
3,851 $452,000
Q4 2021

Feb 14, 2022

BUY
$127.1 - $169.66 $82,360 - $109,939
648 Added 27.35%
3,017 $406,000
Q2 2021

Aug 16, 2021

BUY
$121.62 - $145.29 $78,688 - $94,002
647 Added 37.57%
2,369 $312,000
Q1 2021

Apr 21, 2021

BUY
$124.92 - $173.33 $35,976 - $49,919
288 Added 20.08%
1,722 $222,000
Q4 2020

Feb 10, 2021

BUY
$151.2 - $182.76 $216,820 - $262,077
1,434 New
1,434 $239,000

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $8.33B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Zeke Capital Advisors, LLC Portfolio

Follow Zeke Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zeke Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Zeke Capital Advisors, LLC with notifications on news.